Breast Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 19 – Oct 26, 2026
Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study evaluated circulating eosinophil counts as a noninvasive biomarker for recurrence in HR+/HER2- breast cancer using a discovery cohort (N=472) and a large validation cohort (N=23,170). Higher preoperative eosinophil counts significantly correlated with improved recurrence-free survival and provided additive prognostic value beyond the 21-gene recurrence score in 2,973 patients. In high-risk patients (n=3,471), eosinophil levels predicted which individuals would derive greater benefit from adjuvant CDK4/6 inhibitors, reflecting systemic immune activation and antitumor CD8+ T-cell involvement. These findings establish circulating eosinophils as a clinically accessible liquid biopsy tool for prognosticating recurrence risk and tailoring targeted therapy in the most common breast cancer subtype.
10.1200/JCO-26-00261
Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This Phase III noninferiority trial compared hypofractionated radiotherapy (42.56 Gy in 16 fractions) to conventional fractionation (50 Gy in 25 fractions) in 1,494 patients with high-risk breast cancer requiring internal mammary node irradiation. At 58.1 months median follow-up, the 5-year locoregional recurrence rate was 1.7% for hypofractionation versus 2.2% for conventional treatment, successfully meeting noninferiority criteria (HR 0.69). Hypofractionation significantly reduced grade 3 acute skin toxicity (1.7% vs. 12.2%, p < .001) while maintaining comparable survival outcomes and low cardiopulmonary complications. These results support the 16-fraction regimen as a safe, effective, and more efficient standard of care for high-risk postmastectomy patients needing complex regional nodal irradiation.
10.1200/JCO-25-02843
Oct 12 – Oct 19, 2026
Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This phase 3 randomized clinical trial evaluated camrelizumab plus docetaxel-carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer (TNBC), aiming to improve outcomes with an anthracycline-free regimen. Among 352 mITT patients, the camrelizumab-chemotherapy group achieved a significantly higher pathological complete response (pCR) rate of 57.5% compared to 45.4% with chemotherapy alone, an absolute difference of 12.2% (P=0.014). Grade 3-4 adverse events were manageable, occurring in 24.9% versus 21.8%, with no treatment-related deaths. This promising anthracycline-free regimen offers a clinically relevant strategy to enhance pCR in TNBC patients, warranting further comparison with existing standard chemoimmunotherapy.
10.1016/j.annonc.2026.10.102
Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized noninferiority trial compared hypofractionated postmastectomy radiation therapy (42.56 Gy in 16 fractions) to conventional treatment (50 Gy in 25 fractions) in 898 women with invasive breast cancer undergoing reconstruction. At 24 months, reconstruction complication rates were 12.3% for hypofractionated versus 10.2% for conventional therapy, confirming noninferiority with an estimated difference of -2.1% (95% CI, -6.5 to 2.2). Locoregional recurrence rates at 36 months remained low and statistically similar between groups (1.5% vs. 2.2%), while implant-only reconstructions showed higher complication risks than autologous methods. These findings support the clinical adoption of shorter radiation courses for breast cancer patients, offering comparable safety and oncologic control while significantly reducing treatment duration.
10.1200/JCO-26-00474
Oct 05 – Oct 12, 2026
Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
TOSYMA-2, a multicentre RCT, compared invasive interval cancer rates after digital breast tomosynthesis plus synthesised mammography (DBT+s2D) versus digital mammography (DM) in 99,558 women aged 50-70. At 24 months, invasive interval cancer rates were 14.2 vs 18.6 per 10,000 screen-negative women (adjusted OR 0.76, 95% CI 0.55-1.06, p=0.11), and at 12 months 4.5 vs 6.3 per 10,000 (OR 0.71, 95% CI 0.52-0.97). Although the primary endpoint did not reach statistical significance, the trial suggests about a quarter of invasive interval cancers with DM might be avoided using DBT+s2D. These findings support DBT+s2D as a potentially superior breast cancer screening strategy, though confirmatory evidence is needed.
10.1016/S1470-2045(26)00341-4
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review examines evolving treatment algorithms for HER2-positive breast cancer, focusing on “right-sizing” therapy across early and metastatic disease stages. It highlights the impact of novel agents like trastuzumab deruxtecan and discusses strategies for de-escalating treatment in low-risk patients while intensifying therapy for those with residual disease. The analysis addresses critical evidence gaps in treatment sequencing, maintenance strategies using palbociclib or tucatinib, and the integration of tissue and plasma-based biomarkers. Clinicians can utilize these frameworks to optimize therapeutic selection, aiming to improve the 5-year survival rates already observed in a substantial proportion of metastatic patients.
10.1038/s41571-026-01211-5
Advances in Systemic Treatment of Breast Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This review examines the rapid evolution of systemic breast cancer therapies since 2020, focusing on the integration of targeted agents, antibody-drug conjugates (ADCs), and immunotherapy guided by molecular profiling. Key developments include the foundational role of CDK4/6 inhibitors in HR+/HER2- disease and the transformative impact of trastuzumab deruxtecan in HER2-positive cases. For triple-negative breast cancer, immune checkpoint inhibitors have significantly improved outcomes in both early and metastatic stages, while risk-adapted strategies allow for treatment escalation or de-escalation. These advancements necessitate personalized, biomarker-driven approaches, though challenges remain regarding treatment sequencing, circulating tumor DNA integration, and equitable access to high-cost therapies.
10.1056/NEJMra2500695
Sep 28 – Oct 05, 2026
Giredestrant plus Everolimus in Advanced Breast Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3 randomized trial investigated giredestrant plus everolimus versus standard endocrine therapy plus everolimus in 373 patients with ER-positive, HER2-negative advanced breast cancer progressing after CDK4/6 inhibitors. The giredestrant-everolimus regimen significantly extended median progression-free survival to 10.0 months (vs 5.5 months) in ESR1-mutated tumors (HR 0.38; P<0.001) and to 8.8 months (vs 5.5 months) in the overall population (HR 0.56; P<0.001). This all-oral combination offers a clinically relevant new treatment option for this challenging patient group, particularly those with ESR1 mutations, with a comparable safety profile. It provides a significant improvement in disease control for advanced breast cancer.
10.1056/NEJMoa2602457
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This prospective study evaluated the false-negative rate (FNR) of sentinel lymph node biopsy (SLNB) in 145 patients with locally advanced breast cancer who achieved a clinical nodal response after neoadjuvant chemotherapy. While the SLN identification rate was 74%, the FNR among patients with adequate mapping was only 2.1% (95% CI, 0.1–12.7), with a nodal pathologic complete response rate of 46%. These findings directly address the clinician’s interest in oncology by demonstrating that SLNB can accurately stage the axilla in high-risk breast cancer patients downstaged by systemic therapy. The low FNR suggests that SLNB is a viable alternative to completion axillary lymph node dissection in this specific cancer population, potentially reducing surgical morbidity.
10.1200/JCO-26-01114
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3 randomized trial (CHN HYPOPMRT) compared hypofractionated (43.5 Gy in 15 fractions) versus conventional (50 Gy in 25 fractions) postmastectomy radiotherapy in 810 high-risk breast cancer patients, with a median follow-up of 11.5 years. At 10 years, cumulative locoregional recurrence was 10.3% with conventional and 12.0% with hypofractionated radiotherapy (HR 1.19, 95% CI 0.79-1.82), showing comparable control. Grade 3 adverse events, such as ischemic heart disease, were similar (1% in both groups), with no grade 4-5 events. This supports hypofractionated PMRT as a time-efficient and safe alternative for durable locoregional control in high-risk breast cancer.
10.1016/S1470-2045(26)00297-4
Sep 21 – Sep 28, 2026
Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This retrospective cohort study of 11,156 women from the National Cancer Database evaluated whether surgical margin widths <2 mm increase recurrence risk in ductal carcinoma in situ (DCIS) compared to the standard ≥2 mm threshold. Over a median follow-up of 66.6 months, 445 patients (4%) experienced ipsilateral recurrence, with multivariable analysis showing no significant difference in recurrence risk between negative margin groups (0.01-1.9 mm vs. ≥2 mm) for the overall cohort. However, subgroup analysis revealed that patients younger than 50 years did experience a significantly higher recurrence risk with narrow margins compared to wider margins. These findings suggest that the 2 mm margin guideline may be unnecessarily restrictive for most DCIS patients, though wider margins remain clinically prudent for younger women to minimize local recurrence.
10.1200/JCO-25-02476
Sep 14 – Sep 21, 2026
Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This review synthesizes current evidence to address management uncertainties in premenopausal women with HR+/HER2-negative early breast cancer, a population characterized by aggressive tumor biology. The authors evaluate the roles of adjuvant endocrine therapy, CDK4/6 inhibitors, ovarian function suppression, and genomic assays in guiding chemotherapy and extended therapy choices. While specific numerical trial data are not detailed in the abstract, the work focuses on optimizing individualized care and managing treatment-related toxicities and survivorship. The study provides a pragmatic clinical framework to bridge evidence gaps, directly supporting clinical decision-making for this specific oncological population.
10.1016/j.annonc.2026.09.005
Sep 07 – Sep 14, 2026
Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase III trial randomized 365 patients with HER2-positive advanced breast cancer who had prior trastuzumab and taxane to trastuzumab botidotin or trastuzumab emtansine. Trastuzumab botidotin significantly improved median progression-free survival (11.1 vs 4.4 months; HR 0.39, 95% CI 0.30-0.51; p<0.0001) and objective response rate (76.9% vs 53.0%). Overall survival data were immature but favored the novel agent (HR 0.62). Grade ≥3 adverse events occurred in 69.8% vs 63.7%, with higher ocular toxicity for trastuzumab botidotin, though most resolved with a management algorithm.
10.1200/JCO-26-00602
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This review article aims to optimize risk-adapted neoadjuvant therapy for HER2-positive early-stage breast cancer by examining de-escalation strategies and new treatment options. Randomized trial data indicate carboplatin can be safely omitted for most patients, achieving comparable pathological complete response rates with reduced toxicity. DESTINY-Breast11 and DESTINY-Breast05 trials established fam-trastuzumab deruxtecan-nxki as new FDA-approved options for high-risk disease, directly informing oncology practice. This supports a more precise, individualized approach to caring for patients, highlighting circulating tumor DNA monitoring and functional imaging for future investigation.
10.1200/JCO-26-01423
Aug 31 – Sep 07, 2026
Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This phase 3 randomized clinical trial investigated neoadjuvant anbenitamab and HB1801 for early ERBB2-positive breast cancer, comparing it to standard trastuzumab, pertuzumab, and docetaxel. Among 521 patients, the investigational group achieved a significantly higher total pathological complete response (tpCR) rate of 62.4% versus 51.2% in the control group (absolute difference, 11.4 percentage points; P = .004). Grade 3 or 4 treatment-related adverse events were comparable between groups (29.3% vs 28.3%). This new combination offers an improved, well-tolerated neoadjuvant treatment option for ERBB2-positive breast cancer, with potential to enhance clinical outcomes.
10.1001/jamaoncol.2026.3329
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
The NSABP B-59/GeparDouze trial, a randomized phase 3 study, investigated adding atezolizumab to neoadjuvant chemotherapy for stage II-III triple-negative breast cancer (TNBC). While atezolizumab did not significantly improve the primary endpoint of event-free survival (HR 0.80, P=0.083), a prespecified subgroup analysis showed benefit in patients with clinical lymph node involvement (P=0.039). Treatment-emergent adverse events were higher with atezolizumab (75.3% vs 73.4% grade ≥3). The findings suggest that TNBC subtyping or quantification of tumor-infiltrating lymphocytes could identify patients who benefit from immune checkpoint inhibitors, guiding more targeted therapeutic strategies in cancer care.
10.1038/s41591-026-04565-6
Aug 24 – Aug 31, 2026
Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This review addresses the complex decision-making for systemic therapy in older adults with early-stage breast cancer, balancing disease recurrence risks against treatment harms, by synthesizing current evidence and highlighting data gaps. It discusses optimal management strategies, including novel approaches like adjuvant CDK4/6 inhibitors for HR-positive disease and neoadjuvant pembrolizumab for triple-negative breast cancer. The review emphasizes avoiding both overtreatment, where less intensive approaches may suffice, and undertreatment, which could increase breast cancer-related mortality in higher-risk patients. It provides tools and data to support best practice, guiding clinicians to optimize care and improve outcomes for this specific cancer patient population.
10.1001/jamaoncol.2026.3121
Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This retrospective cohort study assessed the market dynamics and financial implications of biosimilar entry for three anticancer biologics (bevacizumab, rituximab, trastuzumab) using commercial and Medicare data from 14,655 patients with breast, lymphoma, and colorectal cancers. Key findings revealed that biosimilar entry led to an average 3.8% annual decline in reference product average sales price and a 30-31.5% annual decrease in market share. Patients exclusively using biosimilars experienced a $3820 lower mean monthly payer cost and $39.50 lower mean monthly out-of-pocket cost compared to those using reference products. These results suggest that biosimilar competition in oncology reduces costs for both payers and cancer patients, potentially improving access and affordability of crucial cancer treatments.
10.1001/jamaoncol.2026.3128
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This ASCO Living Guideline provides evidence-based recommendations for medical therapies in patients with stage I-III hormone receptor-positive, HER2-negative breast cancer. An Expert Panel systematically reviewed 45 randomized clinical trials and additional studies published from 2018-2026. Key findings confirm endocrine therapy as foundational, with chemotherapy and targeted therapies further reducing recurrence risk and breast cancer death for selected patients. This guideline offers crucial support for clinicians in individualizing treatment selection and sequencing, integrating clinicopathologic features, genomic assays, and patient preferences to optimize care.
10.1200/JCO-26-02034
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
The OlympiA phase III trial investigated 1 year of adjuvant olaparib versus placebo in 1,836 patients with gBRCApv, high-risk HER2-negative early breast cancer, with a 6.1-year median follow-up. Olaparib demonstrated sustained benefits, improving invasive disease-free survival [HR=0.65], distant disease-free survival [HR=0.65], and overall survival [HR=0.72], with a 6-year OS of 87.5% versus 83.2% for placebo. Additionally, it reduced new BRCA-associated breast and ovarian/fallopian tube cancers without increasing adverse event risks. These findings provide strong evidence for adjuvant olaparib in this specific high-risk breast cancer population, offering clinically meaningful improvements in long-term outcomes and disease prevention.
10.1016/j.annonc.2026.08.002
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This independent validation study (CATALINA) compared AI-derived computational tumour-infiltrating lymphocyte (cTIL) scores against pathologist-scored stromal TILs (sTILs) in 1,356 patients with early-stage triple-negative breast cancer from seven randomized trials. Both cTIL and sTIL scores were independently associated with 5-year invasive disease-free survival, with hazard ratios of 0.80 (95% CI 0.73-0.89) and 0.73 (95% CI 0.66-0.82), respectively. While cTIL scores did not provide incremental prognostic value over sTILs, they significantly improved risk discrimination compared to clinicopathological variables alone. These findings support using AI-based TIL quantification as a reproducible prognostic biomarker in oncology, particularly in clinical settings where expert pathologist assessment is limited.
10.1016/S1470-2045(26)00339-6
Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This review evaluates the role of tumour-infiltrating lymphocytes (TILs) as biomarkers in breast cancer, focusing on their potential to predict radiotherapy response. The authors summarize current evidence indicating that high pre-treatment TIL levels are associated with better prognosis and enhanced systemic therapy response, but note that clinical data on TILs and radiotherapy are scarce. They propose integrating TIL assessment into radiation oncology trials and advocate for standardized reporting to enable biomarker-driven personalization of breast radiotherapy. The primary implication is that TILs may serve as a future tool to guide radiotherapy decisions, though further clinical validation is needed.
10.1016/S1470-2045(26)00255-X
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This secondary analysis of the phase 3 APHINITY trial evaluated manual, digital, and AI-based stromal tumour-infiltrating lymphocyte (sTIL) quantification in 4,262 patients with HER2-positive breast cancer. Higher sTIL levels across all methods significantly correlated with improved invasive disease-free survival (HRs 0.41–0.93), with manual scoring showing high reproducibility (ICC 0.84). Notably, node-positive patients with high manual sTILs (≥70%) experienced a 12.1% absolute improvement in 6-year survival when treated with pertuzumab compared to placebo. While manual scoring remains a robust prognostic tool, AI-derived spatial metrics provide complementary data that could enhance scalable immune assessment and treatment stratification in clinical oncology.
10.1016/S1470-2045(26)00247-0
Aug 17 – Aug 24, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This single-arm trial (EA1181) evaluated neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in 2,175 patients with stage II/IIIa HER2-positive breast cancer, focusing on pathologic complete response (pCR) rates and predictors. Overall pCR was 43.8%, with 63.7% in HER2+/ER- and 32.4% in HER2+/ER+ tumors. Independent predictors of higher pCR included ER-negative/low expression, PR-negative/low expression, HER2 IHC 3+, weekly paclitaxel, and high HER2DX pCR score; T3 disease lowered pCR in ER- tumors. These results support using hormone receptor status, HER2 expression level, and HER2DX score to personalize neoadjuvant therapy and predict response.
10.1200/JCO-25-02255
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This secondary analysis of the phase 3 RxPONDER trial evaluated whether pretreatment ovarian reserve markers, specifically anti-Müllerian hormone (AMH), could predict adjuvant chemotherapy benefit in 1,556 women with HR-positive, HER2-negative, node-positive breast cancer. Results demonstrated that patients with normal ovarian reserve (AMH ≥10 pg/ml) derived significant benefit from chemotherapy (IDFS HR 0.46, 95% CI 0.33-0.65), whereas those with low reserve (AMH <10 pg/ml) did not (HR 1.27, P=0.47). AMH proved to be a superior predictor of chemotherapy benefit compared to traditional markers like age or menopausal status, offering a more precise tool for treatment de-escalation. These findings suggest that measuring ovarian reserve can refine patient selection for chemotherapy, potentially sparing a subset of premenopausal women from unnecessary treatment toxicity.
10.1016/j.annonc.2026.05.697
Aug 10 – Aug 17, 2026
Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This prognostic study evaluated tissue-free circulating tumor DNA (ctDNA) assays for molecular residual disease (MRD) detection in 159 patients with early triple-negative breast cancer (TNBC) from the c-TRAK TN phase 2 study. The tissue-free assay, leveraging cancer differential methylation, detected ctDNA in 34.0% of patients, strongly associating with recurrence risk (HR, 27.2; P < .001). It demonstrated a median lead time to recurrence of 7.9 months, outperforming dPCR (5.8 months) and showing good concordance with tumor-informed assays. These findings support the use of tissue-free MRD detection in TNBC surveillance, offering a practical method for earlier recurrence prediction, especially when tumor tissue is unavailable, thereby informing adjuvant therapy decisions.
10.1001/jamaoncol.2026.2833
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 2, open-label, single-arm trial evaluated the safety and efficacy of ivonescimab plus chemotherapy as first-line treatment for 36 patients with locally advanced unresectable or metastatic triple-negative breast cancer. The study reported treatment-related adverse events in 100% of patients (Grade ≥3 in 58.3%) with no deaths. An objective response rate of 80.0% (95% CI: 63.1-91.6) was observed, including 5.7% complete responses and 74.3% partial responses. This research directly addresses a critical need for effective therapies in an aggressive cancer subtype, offering promising first-line treatment data and warranting further investigation.
10.1038/s41591-026-04564-7
Aug 03 – Aug 10, 2026
Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This multicenter randomized clinical trial investigated whether digital patient-reported outcome (PRO) monitoring with alert-based interventions reduces fatigue in 909 patients with metastatic breast cancer (mBC). Participants in the intervention group completed weekly PRO questionnaires via smartphone, triggering alerts to clinicians for predefined symptom deterioration, while controls received usual care. At 6 months, the intervention group showed a clinically meaningful reduction in fatigue (mean difference -5.4 points; 95% CI, -6.6 to -4.1; P < .001), exceeding the MCID of 3.3 points, and improved physical functioning. These findings demonstrate that digital PRO monitoring significantly improves symptom management and physical functioning in mBC patients, supporting its integration into routine oncology practice.
10.1001/jamaoncol.2026.2661
Jul 27 – Aug 03, 2026
End-to-end multimodal pathology foundation model with clinical dialogue.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This study introduces PRISM2, a multimodal foundation model trained on 2.3 million whole-slide images and 14 million pathology-derived question-answer pairs to align histomorphology with clinical reasoning. The model achieved or exceeded the balanced accuracy of existing clinical-grade products for cancer detection in prostate, breast, and breast lymph node tissues (P < 0.05). PRISM2 embeddings consistently matched or outperformed previous models across diagnostic, biomarker, and survival benchmarks, with task-specific fine-tuning significantly improving survival prediction. These results demonstrate that language-supervised pretraining creates generalizable pathology representations, offering a scalable tool for high-accuracy cancer diagnostics and prognostic modeling in clinical practice.
10.1038/s41591-026-04521-4
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This I-SPY2 randomized clinical trial investigated adding dual immune checkpoint blockade (cemiplimab and fianlimab) to neoadjuvant chemotherapy (NAC) for early-stage, high-risk ERBB2-negative breast cancer. The combination significantly increased pathologic complete response (pCR) rates compared to NAC alone, achieving 44% vs 21% overall, 53% vs 29% in triple-negative, and 36% vs 14% in HR-positive/ERBB2-negative disease. While 21% experienced adrenal insufficiency, the regimen was highly effective in ImPrint positive patients. These findings suggest a promising new neoadjuvant strategy for specific breast cancer subtypes, warranting further definitive trials to improve patient outcomes.
10.1001/jamaoncol.2026.2576
Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This international Delphi study utilized a panel of 36 experts to establish consensus on local management strategies for second ipsilateral breast cancer events (iBCEs) following initial breast-conserving therapy. Consensus was achieved on 80% of items, with 100% agreement that second breast-conserving therapy is a viable option for selected patients, particularly those with a recurrence interval of at least 60 months and luminal molecular profiles. The guidelines clarify that HER2-positive or triple-negative subtypes are not absolute contraindications for breast conservation, while emphasizing the necessity of clear surgical margins and tumor bed reirradiation. These findings provide clinicians with a structured framework for individualized treatment planning and shared decision-making in the complex management of recurrent breast cancer.
10.1016/S1470-2045(26)00177-4
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
The SUPREMO QOL substudy, a phase 3 randomized controlled trial, assessed 5-year quality of life (QOL) effects of postmastectomy chest wall radiotherapy (CWRT) versus no CWRT in 989 UK intermediate-risk breast cancer patients. At 5 years, CWRT significantly worsened chest wall symptoms (effect estimate 1.99 [95% CI 0.36-3.62]; p=0.017), with no significant differences in global QOL, fatigue, or physical function. Patients receiving CWRT after axillary lymph node clearance experienced even worse chest wall symptoms (difference -5.29 [95%CI -8.53 to -2.05]; p=0.0015). This study highlights that while CWRT may not impact overall survival, it can negatively affect chest wall QOL in breast cancer patients, informing shared decision-making regarding adjuvant therapy.
10.1016/S1470-2045(26)00122-1
Jul 20 – Jul 27, 2026
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This Phase III noninferiority trial compared hypofractionated (40Gy/15fx) versus standard (50Gy/25fx) locoregional radiotherapy in 2,908 high-risk breast cancer patients. Results demonstrated that 3-year lymphedema rates were 8.0% for hypofractionation compared to 9.4% for standard treatment (OR 0.84, p=0.27), successfully meeting the noninferiority margin. No significant differences were observed in locoregional recurrence (HR 0.96), distant recurrence (HR 1.10), or breast cancer mortality (HR 1.25) over a median follow-up of 5.25 years. These findings support the clinical adoption of hypofractionated locoregional radiotherapy as a safe, effective, and more convenient standard of care for high-risk breast cancer patients.
10.1200/JCO-25-02705